secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTELLIGENT BIO SOLUTIONS INC. (INBS)
CIK:        0001725430
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001493152-23-039953
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intelligent Bio Solutions Q1 FY2024 revenue up 191% to $0.91M; net loss widens to $2.4M
--------------------------------------------------------------------------------

- Revenue + government support income of $0.91M vs $0 in year-ago quarter; sales of goods $0.8M from IFP acquisition.
- Net loss attributable to INBS of $2.4M vs $1.2M; driven by IFP combined results offset by $131,250 fair value gain.
- Cash and equivalents $0.2M as of Sep 30; raised ~$4.378M ($3.35M net) in October 2023 public offering.
- Expanded into New Zealand and South America (TSCOM SPA distribution deal); added eight new Australian customers.
- Completed development milestone for ketamine and tramadol assays; ISO 13485:2016 recertified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725430/000149315223039953/0001493152-23-039953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725430/000149315223039953/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer